In a groundbreaking shift for medicine, Neion Bio is introducing a method to produce biological medicines using chicken eggs. This change could make life-saving therapies far more affordable and accessible for everyday people.

Rethinking Biomanufacturing

Current methods for producing biological medicines are expensive and inefficient. Most rely on large bioreactors using Chinese hamster ovary (CHO) cells, a standard that has existed for decades. According to Samuel Levin, cofounder and chief technical officer of Neion Bio, these systems are kept running at a high cost, with production reaching thousands of dollars per gram. This reality leaves many patients unable to access necessary treatments.

Neion Bio is changing this narrative. Founded by Levin and aerospace engineer Dimi Kellari, the company wants to replace massive bioreactors with something much simpler: chicken eggs. By engineering chickens to lay eggs enriched with medicinal proteins, they aim to create a more efficient and sustainable production line. Levin emphasizes that a small chicken farm could potentially meet the global demand for a popular drug like Humira.

Farm-to-Medicine Approach

Levin describes Neion Bio’s innovative process as “farming medicines.” The company is moving towards an autonomous, self-replicating biotech system that utilizes the natural protein production capabilities of chicken eggs. This approach is expected to simplify the complex systems currently in place, leading to both cost savings and increased efficiency.

In a recent interview, Levin explained that their inspiration came from decades of research into using chicken eggs as a manufacturing tool. They were particularly excited by recent advancements in genetic engineering that allow for faster and more precise editing of chicken DNA. This shift means that they can harness existing biological machinery to produce therapeutic proteins more effectively.

Precision Genetic Engineering

Despite the advantages of new technologies, the genetic engineering of chickens is no small feat. Levin acknowledges the difficulties involved but points out that they have already created five genetically engineered chicken lines in just over a year. This rapid progress is possible due to the foundation laid by previous research and collaboration with renowned genome engineers.

The method involves inserting genes that code for desired medicinal proteins directly into the natural protein production sites of the chicken’s genome. By using the body’s own systems, Neion Bio optimizes the production process, making it not just innovative but also a natural fit.

Potential Impact on Healthcare Costs

Levin and Kellari aspire to drastically reduce costs in biomanufacturing, aiming for under $10 per gram for monoclonal antibodies. These aspirations align with philanthropic goals set by organizations like the Gates Foundation. The timeline for these advanced therapeutics is optimistic, with plans for regulatory submissions in the next year, enabling products to enter the market shortly thereafter.

In five years, Neion Bio aims to redefine access to therapeutics, allowing for local manufacturing that does not compromise on quality. Their goal is to produce a wide range of medicines affordably and efficiently, unlocking new possibilities in healthcare.

What this means for you

These advancements in biomanufacturing could lead to more affordable medical treatments, making life-saving drugs more accessible. If you ever need to review medical consent documents, legal-document-to-plain-english-translator/”>AI legalese decoder can translate it into plain English in seconds. With these innovations, healthcare may become not just better but also far more equitable.

Source: https://www.the-scientist.com/chicken-eggs-become-bioreactors-to-brew-low-cost-medicines-74459